PRMT5 expression levels were higher in NSCLC, which exhibits enhanced signalling of HH, a known PRMT5 inducer34, than in conditions such as oesophagogastric, colorectal, prostate, and pancreatic cancers43–46 (Supplementary Fig. 1e). Here, PRMT5 is linked to non-small cell lung carcinoma.